SRR12696789
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.600
- MYC_TARGETS_V1+0.600
- MYC_TARGETS_V2+0.600
- G2M_CHECKPOINT+0.500
- OXIDATIVE_PHOSPHORYLATION+0.500
- DNA_REPAIR+0.400
- INTERFERON_ALPHA_RESPONSE+0.400
- MTORC1_SIGNALING+0.400
- PROTEIN_SECRETION+0.400
- UNFOLDED_PROTEIN_RESPONSE+0.400
Top 10 suppressed
- PANCREAS_BETA_CELLS-0.300
- WNT_BETA_CATENIN_SIGNALING-0.300
- ANGIOGENESIS-0.200
- APICAL_JUNCTION-0.200
- KRAS_SIGNALING_DN-0.200
- MYOGENESIS-0.200
- BILE_ACID_METABOLISM-0.100
- UV_RESPONSE_DN-0.100
- COAGULATION+0.000
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.000
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR12696781 | — | — | 0.888 |
| 2 | SRR12696772 | — | — | 0.885 |
| 3 | MNG533 | — | — | 0.859 |
| 4 | MDT-AP-0368 | Med | Medulloblastoma | 0.858 |
| 5 | MNG1200 | — | — | 0.858 |
| 6 | TCGA-A8-A09I-01A-22R-A034-07 | — | C | 0.857 |
| 7 | SRR1313147 | — | E | 0.854 |
| 8 | SRR6013495 | — | cohortA1 | 0.846 |
| 9 | TCGA-73-4666-01A-01R-1206-07 | — | cohortA1 | 0.839 |
| 10 | d5610bbc-93c5-4ca5-b687-f955d1b84c92 | — | — | 0.837 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 33 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.600 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.600 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.600 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.500 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.500 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.400 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.400 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.400 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.400 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.400 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.300 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.300 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.300 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.300 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.300 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.300 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.300 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.200 | Temsirolimus | — uncovered |
| APOPTOSIS | 0.200 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.200 | Remibrutinib | — uncovered |